PPD to discover biomarkers for PDL BioPharma

By Elaine Rigoli

Tampa, Fla., May 2 - PPD, Inc. has signed an agreement to perform comprehensive molecular profiling to discover biomarkers for PDL BioPharma, Inc.

Under the agreement, PPD's biomarker discovery sciences group will examine specified sample sets using DeepLook analysis, its proprietary integrated platform for mass spectrometry-based discovery of biomarkers.

Financial terms of the agreement were not disclosed.

Biomarkers are components of bodily fluids or tissues that are indicative of the presence of disease, its progression or the response to therapeutic intervention.

PDL BioPharma is a biopharmaceutical company focused on developing therapies for severe or life-threatening illnesses and is located in Fremont, Calif.

PPD is a global contract research organization based in Wilmington, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.